ArticleJournal of multidisciplinary healthcare2025
Diagnostic Efficacy of Combined N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) and Cardiac Troponin I (cTnI) Testing in Myocardial Injury of Children with
Article in Journal of multidisciplinary healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development of a nomogram to predict acute liver injury in children withFrontiers in pediatrics · 2026Article
- High-Sensitivity Troponin I and NT-proBNP as Early Indicators of Disease Severity and Prognostic Markers in Immune Checkpoint Inhibitor-Associated Fulminant Myocarditis.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the diagnostic performance of combined N-terminal pro-brain natriuretic peptide (NT-proBNP) and cardiac troponin I (cTnI) testing for myocardial injury in children with Mycoplasma pneumoniae pneumonia (MPP). Methods: This retrospective study included 103 pediatric patients with MPP complicated by myocardial injury admitted between December 2021 and December 2023. Patients were stratified by New York Heart Association (NYHA) functional class (I-IV). Demographic and clinical characteristics, biomarker levels, and diagnostic accuracy were analyzed. ROC curves were used to assess diagnostic performance of single and combined biomarkers. Results: No significant differences were observed in age or gender across NYHA classes. However, BMI Z-scores declined significantly with worsening class (P = 0.013), while heart rate, systolic blood pressure, fever duration, respiratory rate, and hospital stay increased progressively (all P < 0.01), indicating disease severity. Serum NT-proBNP and cTnI levels rose in parallel with advancing NYHA class (P < 0.001 between all adjacent groups). A strong positive correlation was found between NT-proBNP and cTnI (r = 0.617, P < 0.001). Combined biomarker testing demonstrated superior diagnostic accuracy (AUC = 0.914), outperforming NT-proBNP (AUC = 0.877) and cTnI alone (AUC = 0.739). The combination improved sensitivity (94.15%) and specificity (95.19%), reducing false negatives and enhancing risk stratification. Notably, 80% of NYHA class III-IV cases were correctly reclassified into the high-risk group, with a net reclassification improvement (NRI) of +34.2% (P = 0.002). Conclusion: Combined NT-proBNP and cTnI testing provides robust diagnostic efficacy for myocardial injury in pediatric MPP. This dual-biomarker strategy enables earlier identification of high-risk patients and supports more precise clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.